Literature DB >> 11312327

Equine infectious anemia virus genomic evolution in progressor and nonprogressor ponies.

C Leroux1, J K Craigo, C J Issel, R C Montelaro.   

Abstract

A primary mechanism of lentivirus persistence is the ability of these viruses to evolve in response to biological and immunological selective pressures with a remarkable array of genetic and antigenic variations that constitute a perpetual natural experiment in genetic engineering. A widely accepted paradigm of lentivirus evolution is that the rate of genetic variation is correlated directly with the levels of virus replication: the greater the viral replication, the more opportunities that exist for genetic modifications and selection of viral variants. To test this hypothesis directly, we examined the patterns of equine infectious anemia virus (EIAV) envelope variation during a 2.5-year period in experimentally infected ponies that differed markedly in clinical progression and in steady-state levels of viral replication as indicated by plasma virus genomic RNA assays. The results of these comprehensive studies revealed for the first time similar extents of envelope gp90 variation in persistently infected ponies regardless of the number of disease cycles (one to six) and viremia during chronic disease. The extent of envelope variation was also independent of the apparent steady-state levels of virus replication during long-term asymptomatic infection, varying from undetectable to 10(5) genomic RNA copies per ml of plasma. In addition, the data confirmed the evolution of distinct virus populations (genomic quasispecies) associated with sequential febrile episodes during acute and chronic EIA and demonstrated for the first time ongoing envelope variation during long-term asymptomatic infections. Finally, comparison of the rates of evolution of the previously defined EIAV gp90 variable domains demonstrated distinct differences in the rates of nucleotide and amino acid sequence variation, presumably reflecting differences in the ability of different envelope domains to respond to immune or other biological selection pressures. Thus, these data suggest that EIAV variation can be associated predominantly with ongoing low levels of virus replication and selection in target tissues, even in the absence of substantial levels of plasma viremia, and that envelope variation continues during all stages of persistent infection as the virus successfully avoids clearance by host defense mechanisms.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11312327      PMCID: PMC114210          DOI: 10.1128/JVI.75.10.4570-4583.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus.

Authors:  S A Hammond; F Li; B M McKeon; S J Cook; C J Issel; R C Montelaro
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Tissue sites of persistent infection and active replication of equine infectious anemia virus during acute disease and asymptomatic infection in experimentally infected equids.

Authors:  S M Harrold; S J Cook; R F Cook; K E Rushlow; C J Issel; R C Montelaro
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

3.  Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS.

Authors:  B R Starcich; B H Hahn; G M Shaw; P D McNeely; S Modrow; H Wolf; E S Parks; W P Parks; S F Josephs; R C Gallo
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

4.  Antigenic variation and lentivirus persistence: variations in envelope gene sequences during EIAV infection resemble changes reported for sequential isolates of HIV.

Authors:  S L Payne; F D Fang; C P Liu; B R Dhruva; P Rwambo; C J Issel; R C Montelaro
Journal:  Virology       Date:  1987-12       Impact factor: 3.616

5.  The accuracy of reverse transcriptase from HIV-1.

Authors:  J D Roberts; K Bebenek; T A Kunkel
Journal:  Science       Date:  1988-11-25       Impact factor: 47.728

6.  Endothelial cell infection in vivo by equine infectious anaemia virus.

Authors:  J Lindsay Oaks; Catherine Ulibarri; Timothy B Crawford
Journal:  J Gen Virol       Date:  1999-09       Impact factor: 3.891

7.  Fidelity of HIV-1 reverse transcriptase.

Authors:  B D Preston; B J Poiesz; L A Loeb
Journal:  Science       Date:  1988-11-25       Impact factor: 47.728

8.  Course and extent of variation of equine infectious anemia virus during parallel persistent infections.

Authors:  S L Payne; O Salinovich; S M Nauman; C J Issel; R C Montelaro
Journal:  J Virol       Date:  1987-04       Impact factor: 5.103

9.  Genetic analysis of viral variants selected in transmission of human immunodeficiency viruses to newborns.

Authors:  S Kliks; C H Contag; H Corliss; G Learn; A Rodrigo; D Wara; J I Mullins; J A Levy
Journal:  AIDS Res Hum Retroviruses       Date:  2000-09-01       Impact factor: 2.205

10.  V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies.

Authors:  A Ly; L Stamatatos
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

View more
  27 in total

1.  Subpopulations of equine infectious anemia virus Rev coexist in vivo and differ in phenotype.

Authors:  Prasith Baccam; Robert J Thompson; Yuxing Li; Wendy O Sparks; Michael Belshan; Karin S Dorman; Yvonne Wannemuehler; J Lindsay Oaks; James L Cornette; Susan Carpenter
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

2.  Molecular detection, epidemiology, and genetic characterization of novel European field isolates of equine infectious anemia virus.

Authors:  Katia Cappelli; Stefano Capomaccio; Frank R Cook; Michela Felicetti; Maria Luisa Marenzoni; Giacomo Coppola; Andrea Verini-Supplizi; Mauro Coletti; Fabrizio Passamonti
Journal:  J Clin Microbiol       Date:  2010-11-17       Impact factor: 5.948

3.  Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range.

Authors:  Jaume Jorba; Ray Campagnoli; Lina De; Olen Kew
Journal:  J Virol       Date:  2008-02-20       Impact factor: 5.103

4.  Envelope variation as a primary determinant of lentiviral vaccine efficacy.

Authors:  Jodi K Craigo; Baoshan Zhang; Shannon Barnes; Tara L Tagmyer; Sheila J Cook; Charles J Issel; Ronald C Montelaro
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-10       Impact factor: 11.205

5.  Antibody escape kinetics of equine infectious anemia virus infection of horses.

Authors:  Elissa J Schwartz; Seema Nanda; Robert H Mealey
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

6.  Amino acid mutations in the env gp90 protein that modify N-linked glycosylation of the Chinese EIAV vaccine strain enhance resistance to neutralizing antibodies.

Authors:  Xiue Han; Ping Zhang; Wei Yu; Wenhua Xiang; Xiaodong Li
Journal:  Virus Genes       Date:  2016-08-29       Impact factor: 2.332

7.  Horses naturally infected with EIAV harbor 2 distinct SU populations but are monophyletic with respect to IN.

Authors:  Diana T Cervantes; Judith M Ball; John Edwards; Susan Payne
Journal:  Virus Genes       Date:  2016-01-06       Impact factor: 2.332

8.  Epitope shifting of gp90-specific cellular immune responses in EIAV-infected ponies.

Authors:  Chong Liu; Sheila J Cook; Jodi K Craigo; Frank R Cook; Charles J Issel; Ronald C Montelaro; David W Horohov
Journal:  Vet Immunol Immunopathol       Date:  2014-08-10       Impact factor: 2.046

9.  Restriction of equine infectious anemia virus by equine APOBEC3 cytidine deaminases.

Authors:  Jörg Zielonka; Ignacio G Bravo; Daniela Marino; Elea Conrad; Mario Perković; Marion Battenberg; Klaus Cichutek; Carsten Münk
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

10.  An EIAV field isolate reveals much higher levels of subtype variability than currently reported for the equine lentivirus family.

Authors:  Jodi K Craigo; Shannon Barnes; Baoshan Zhang; Sheila J Cook; Laryssa Howe; Charles J Issel; Ronald C Montelaro
Journal:  Retrovirology       Date:  2009-10-20       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.